Our Guest: Sharon Rogers, CEO at AmyriAD TherapeuticsWhat you'll get out of this episode:
Rogers' background
An overview of AmyriAD Therapeutics 
The company's lead compound, AD101
Their clinical trials & what they're showing
Launching a Phase 3 Study
What's next?

Our sponsors for this episode are Sage Growth Partners & FlipMDSage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartnersFlipMD is an open, competitive marketplace of physicians only offering their consulting services to a wide range of client industries. The ultimate goal of flipMD is to be the best source of physician talent for any industry. The platform is very simple to use, you post a job for free with the specific scope of work and your budget. After the job posting, our physicians respond directly to you with their best offer for the work. Once you accept an offer, you fund the project. Once you receive satisfactory work, you accept and the funds are released to your expert physician consultant. For more information, please go to https://flip-md.com/ & follow FlipMD on social media - @flipmdTo learn more about AmyriAD Therapeutics please use the links below:- Website - LinkedInAlso, be sure to follow Slice of Healthcare on our social channels:- Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter